AbCellera Biologics (ABCL) Competitors $4.60 -0.17 (-3.50%) As of 02:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABCL vs. RNA, MRUS, TGTX, PTCT, KRYS, ACLX, ACAD, PCVX, ARWR, and MENSShould you be buying AbCellera Biologics stock or one of its competitors? The main competitors of AbCellera Biologics include Avidity Biosciences (RNA), Merus (MRUS), TG Therapeutics (TGTX), PTC Therapeutics (PTCT), Krystal Biotech (KRYS), Arcellx (ACLX), ACADIA Pharmaceuticals (ACAD), Vaxcyte (PCVX), Arrowhead Pharmaceuticals (ARWR), and Jyong Biotech (MENS). These companies are all part of the "pharmaceutical products" industry. AbCellera Biologics vs. Its Competitors Avidity Biosciences Merus TG Therapeutics PTC Therapeutics Krystal Biotech Arcellx ACADIA Pharmaceuticals Vaxcyte Arrowhead Pharmaceuticals Jyong Biotech AbCellera Biologics (NASDAQ:ABCL) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership. Which has better earnings & valuation, ABCL or RNA? AbCellera Biologics has higher revenue and earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbCellera Biologics$32.88M41.84-$162.86M-$0.55-8.37Avidity Biosciences$10.90M549.60-$322.30M-$3.56-11.53 Which has more risk and volatility, ABCL or RNA? AbCellera Biologics has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500. Do institutionals and insiders hold more shares of ABCL or RNA? 61.4% of AbCellera Biologics shares are owned by institutional investors. 28.9% of AbCellera Biologics shares are owned by company insiders. Comparatively, 3.8% of Avidity Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is ABCL or RNA more profitable? AbCellera Biologics has a net margin of -511.88% compared to Avidity Biosciences' net margin of -4,247.77%. AbCellera Biologics' return on equity of -16.17% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets AbCellera Biologics-511.88% -16.17% -12.24% Avidity Biosciences -4,247.77%-33.45%-30.22% Does the media prefer ABCL or RNA? In the previous week, Avidity Biosciences had 15 more articles in the media than AbCellera Biologics. MarketBeat recorded 22 mentions for Avidity Biosciences and 7 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.93 beat Avidity Biosciences' score of 0.71 indicating that AbCellera Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avidity Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate ABCL or RNA? AbCellera Biologics presently has a consensus price target of $8.00, suggesting a potential upside of 73.80%. Avidity Biosciences has a consensus price target of $68.32, suggesting a potential upside of 66.38%. Given AbCellera Biologics' higher possible upside, research analysts plainly believe AbCellera Biologics is more favorable than Avidity Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AbCellera Biologics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00Avidity Biosciences 0 Sell rating(s) 0 Hold rating(s) 18 Buy rating(s) 1 Strong Buy rating(s) 3.05 SummaryAbCellera Biologics beats Avidity Biosciences on 11 of the 16 factors compared between the two stocks. Get AbCellera Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABCL vs. The Competition Export to ExcelMetricAbCellera BiologicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.39B$3.07B$5.65B$10.26BDividend YieldN/A2.36%5.68%4.61%P/E Ratio-8.4520.6875.7026.05Price / Sales41.84397.57514.05168.79Price / CashN/A45.9137.5661.52Price / Book1.299.6212.876.29Net Income-$162.86M-$52.73M$3.29B$270.94M7 Day Performance-2.48%0.59%-0.33%-0.30%1 Month Performance8.82%6.27%3.77%6.20%1 Year Performance88.65%18.55%68.18%28.32% AbCellera Biologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABCLAbCellera Biologics2.9493 of 5 stars$4.60-3.5%$8.00+73.8%+89.3%$1.39B$32.88M-8.45500RNAAvidity Biosciences2.0899 of 5 stars$40.22-10.1%$68.94+71.4%-1.8%$5.17B$10.73M-11.30190Analyst ForecastHigh Trading VolumeMRUSMerus2.7407 of 5 stars$68.09-2.1%$88.75+30.3%+43.2%$5.15B$56.23M-12.3837Positive NewsTGTXTG Therapeutics4.2637 of 5 stars$31.75-1.3%$46.25+45.7%+51.9%$5.04B$329M85.81290PTCTPTC Therapeutics3.9796 of 5 stars$58.98-3.5%$69.00+17.0%+62.9%$4.69B$1.76B8.461,410Positive NewsKRYSKrystal Biotech4.941 of 5 stars$155.71+8.4%$209.00+34.2%-9.7%$4.51B$290.52M31.65210Positive NewsHigh Trading VolumeACLXArcellx2.3103 of 5 stars$75.20-1.3%$114.31+52.0%-6.7%$4.17B$107.94M-21.9980ACADACADIA Pharmaceuticals4.3612 of 5 stars$24.67+4.5%$29.65+20.2%+34.2%$4.16B$957.80M18.55510Trending NewsAnalyst ForecastOptions VolumePCVXVaxcyte2.0121 of 5 stars$31.00-3.6%$106.25+242.7%-71.6%$4.02BN/A-7.54160Positive NewsARWRArrowhead Pharmaceuticals4.1362 of 5 stars$28.67-3.5%$43.14+50.5%+63.0%$3.96B$572.98M-22.40400MENSJyong BiotechN/A$51.82-15.7%N/AN/A$3.94BN/A0.0031Gap DownHigh Trading Volume Related Companies and Tools Related Companies Avidity Biosciences Competitors Merus Competitors TG Therapeutics Competitors PTC Therapeutics Competitors Krystal Biotech Competitors Arcellx Competitors ACADIA Pharmaceuticals Competitors Vaxcyte Competitors Arrowhead Pharmaceuticals Competitors Jyong Biotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABCL) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbCellera Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABCL Stock Alerts